86 related articles for article (PubMed ID: 25436812)
1. Young male with fanconi anemia and EGFR-mutant non-small-cell lung cancer.
Cathcart-Rake E; Lopez-Chavez A
J Thorac Oncol; 2014 Nov; 9(11):e83-5. PubMed ID: 25436812
[No Abstract] [Full Text] [Related]
2. EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.
Dowell JE; Minna JD
Nat Clin Pract Oncol; 2006 Apr; 3(4):170-1. PubMed ID: 16596125
[No Abstract] [Full Text] [Related]
3. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.
Nagai Y; Miyazawa H; Huqun ; Tanaka T; Udagawa K; Kato M; Fukuyama S; Yokote A; Kobayashi K; Kanazawa M; Hagiwara K
Cancer Res; 2005 Aug; 65(16):7276-82. PubMed ID: 16105816
[TBL] [Abstract][Full Text] [Related]
4. A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non-Small Cell Lung Cancer Patient.
Lee JS; Hur JY; Kim HJ; Lee KY; Kim WS
J Thorac Oncol; 2017 Nov; 12(11):e179-e181. PubMed ID: 29074208
[No Abstract] [Full Text] [Related]
5. Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
Uramoto H; Mitsudomi T
Br J Cancer; 2007 Mar; 96(6):857-63. PubMed ID: 17325698
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
[TBL] [Abstract][Full Text] [Related]
7. The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic.
Politi K; Ayeni D; Lynch T
Cancer Cell; 2015 Jun; 27(6):751-3. PubMed ID: 26058074
[TBL] [Abstract][Full Text] [Related]
8. [ARMS method verified EGFR gene mutations and its clinical significance in patients with non-small cell lung cancer].
Xu HY; Hong WL; Xie SS; Pan XD; Bai YH; Lin XY; Chen BC
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2014 Mar; 30(2):158-60. PubMed ID: 25016871
[No Abstract] [Full Text] [Related]
9. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Jänne PA; Johnson BE
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
[TBL] [Abstract][Full Text] [Related]
10. Somatic mutations of EGFR, ERBB2, ERBB3 and ERBB4 in juxtamembrane activating domains are rare in non-small cell lung cancers.
Park SW; Chung NG; Han JY; Eom HS; Yoo NJ; Lee SH
APMIS; 2010 Jan; 118(1):83-4. PubMed ID: 20041876
[No Abstract] [Full Text] [Related]
11. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
Friedrich MJ
J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503
[No Abstract] [Full Text] [Related]
12. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
Gridelli C
Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
[No Abstract] [Full Text] [Related]
13. [Consensus for epidermal growth factor receptor gene mutation detection in non-small cell lung cancer].
Consensus Group for Epidermal Growth Factor Receptor Gene Mutation Detection in Non-Small Cell Lung Cancer
Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):700-2. PubMed ID: 22321552
[No Abstract] [Full Text] [Related]
14. Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
Reddy GK
Clin Lung Cancer; 2005 Nov; 7(3):163-5. PubMed ID: 16354309
[No Abstract] [Full Text] [Related]
15. Spatiotemporal T790M heterogeneity in a patient with EGFR-mutant non-small-cell lung cancer.
Hata A; Masago K; Katakami N; Imai Y; Yatabe Y
J Thorac Oncol; 2014 Aug; 9(8):e64-5. PubMed ID: 25157783
[No Abstract] [Full Text] [Related]
16. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.
Bell DW; Gore I; Okimoto RA; Godin-Heymann N; Sordella R; Mulloy R; Sharma SV; Brannigan BW; Mohapatra G; Settleman J; Haber DA
Nat Genet; 2005 Dec; 37(12):1315-6. PubMed ID: 16258541
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.
Su KY; Chen HY; Li KC; Kuo ML; Yang JC; Chan WK; Ho BC; Chang GC; Shih JY; Yu SL; Yang PC
J Clin Oncol; 2012 Feb; 30(4):433-40. PubMed ID: 22215752
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
Johnson BE; Jänne PA
Cancer Res; 2005 Sep; 65(17):7525-9. PubMed ID: 16140912
[TBL] [Abstract][Full Text] [Related]
19. Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer.
Zhang X; Chang A
J Med Genet; 2007 Mar; 44(3):166-72. PubMed ID: 17158592
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors.
Cohen V; Agulnik JS; Ang C; Kasymjanova G; Batist G; Small D; Brandao G; Chong G; Miller WH
Cancer; 2010 Sep; 116(18):4309-17. PubMed ID: 20549828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
